Analytical Data
-
Gene name
TLR3/CD283
- Application
-
Alternative Names
TLR3; CD283; IIAE2
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6PCD4
-
Expression Region
S23-E703
-
Molecular Weight
120-140 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TLR3, or Toll-like receptor 3, is a vital component of the innate immune system, playing a crucial role in the recognition of viral infections and the subsequent activation of immune responses. It specifically identifies double-stranded RNA, a common byproduct of viral replication, which triggers signaling pathways that lead to the production of pro-inflammatory cytokines and type I interferons. The exploration of TLR3/CD283 recombinant protein is significant for understanding its molecular mechanisms and potential therapeutic applications, particularly in antiviral therapies and vaccine development. The ability to produce recombinant TLR3 enhances research on its structure-function relationships and facilitates the study of its interactions with various ligands. Additionally, TLR3 has been implicated in various diseases, including autoimmune disorders and cancers, making it an attractive target for drug development. By investigating the properties and effects of TLR3/CD283 recombinant protein, researchers aim to elucidate its role in immune regulation and identify novel strategies to manipulate TLR3 pathways for therapeutic benefits. This research can ultimately contribute to the design of immunomodulatory treatments that enhance the immune response against pathogens or mitigate undesirable inflammatory reactions.
